Metropolitan Life Insurance Co. NY Increases Holdings in Madrigal Pharmaceuticals Inc (MDGL)

Share on StockTwits

Metropolitan Life Insurance Co. NY raised its position in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) by 357.0% during the fourth quarter, HoldingsChannel reports. The firm owned 2,262 shares of the biopharmaceutical company’s stock after purchasing an additional 1,767 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Madrigal Pharmaceuticals were worth $255,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Candriam Luxembourg S.C.A. lifted its holdings in Madrigal Pharmaceuticals by 125.4% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 31,450 shares of the biopharmaceutical company’s stock valued at $3,545,000 after purchasing an additional 17,500 shares in the last quarter. Highbridge Capital Management LLC lifted its holdings in Madrigal Pharmaceuticals by 37.5% in the 4th quarter. Highbridge Capital Management LLC now owns 13,750 shares of the biopharmaceutical company’s stock valued at $1,550,000 after purchasing an additional 3,750 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in Madrigal Pharmaceuticals by 149.1% in the 4th quarter. Two Sigma Advisers LP now owns 19,698 shares of the biopharmaceutical company’s stock valued at $2,220,000 after purchasing an additional 11,789 shares in the last quarter. HRS Investment Holdings LLC lifted its holdings in Madrigal Pharmaceuticals by 100.0% in the 4th quarter. HRS Investment Holdings LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $564,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Mackay Shields LLC lifted its holdings in Madrigal Pharmaceuticals by 6.7% in the 4th quarter. Mackay Shields LLC now owns 2,561 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 161 shares in the last quarter. Institutional investors own 58.28% of the company’s stock.

Several research analysts have recently commented on MDGL shares. ValuEngine upgraded Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, March 15th. UBS Group lifted their price target on Madrigal Pharmaceuticals to $143.00 and gave the stock a “positive” rating in a report on Thursday, March 28th. BidaskClub upgraded Madrigal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, February 25th. Svb Leerink started coverage on Madrigal Pharmaceuticals in a report on Friday, February 22nd. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Zacks Investment Research upgraded Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a report on Wednesday, January 9th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $223.36.

NASDAQ MDGL opened at $126.83 on Friday. Madrigal Pharmaceuticals Inc has a 52 week low of $91.56 and a 52 week high of $325.98. The firm has a market cap of $1.96 billion, a PE ratio of -57.13 and a beta of 1.19.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) EPS for the quarter, hitting the consensus estimate of ($0.75). During the same period in the previous year, the business posted ($0.67) EPS. As a group, research analysts expect that Madrigal Pharmaceuticals Inc will post -3.99 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Highlight Press and is the property of of Highlight Press. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://highlightpress.com/2019/04/13/metropolitan-life-insurance-co-ny-increases-holdings-in-madrigal-pharmaceuticals-inc-mdgl.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Read More: What is a stock split?

Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL).

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.